Erschienen in:
30.06.2017 | Editorial
Towards precision medicine for type 2 diabetes
verfasst von:
Haruhiko Osawa
Erschienen in:
Diabetology International
|
Ausgabe 3/2017
Einloggen, um Zugang zu erhalten
Excerpt
The key to establishing precision medicine for type 2 diabetes (T2D) is to use single nucleotide polymorphisms (SNPs) to determine susceptibility to T2D. Since 2007, genome-wide association studies (GWASs) based on the common disease–common variant hypothesis have been conducted and have identified ~100 T2D susceptibility SNPs, although these SNPs influence the T2D susceptibility only weakly [
1]. The major SNPs can explain approximately 10% of the T2D heritability; the rest is called the “missing heritability” [
2]. Whole-genome or exome sequencing was expected to find SNPs with low minor allele frequencies and relatively strong effects. However, T2D susceptibility is unlikely to be mainly determined by low-frequency SNPs [
3]. …